This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
Chief Executive Officer
Mr. Michlin brings two decades of experience in growing biomedical organizations.
His proficiency in corporate finance, capital markets and business management and development has played a crucial role in the success of leading organizations throughout the Israeli biotech industry.
He joined BrainsWay in 2015 to serve as a director on its board and provides exceptional guidance.
Mr. Michlin brings extensive expertise in steering biomedical companies to success.
He possesses the right blend of strategic acumen, interpersonal skills, relationship assets and management capabilities.
For eight years, he served as president and CEO of Yissum, the technology transfer company of Israel’s Hebrew University in Jerusalem.
At Yissum, he facilitated and oversaw numerous corporate transactions and initiatives in partnership with corporations across the globe and funded and served as chairman of a number of companies including Integra Holdings, a healthcare investment company and Agrinnovation, an investment fund focusing on Agriculture and food sciences.
Mr. Michlin also served as chairman for QLIGHT Nanotech Ltd., a developer of semiconductors and nanocrystals, which he led from the company’s founding until its acquisition by Merck. He also served as co-chairman of ITTN, the Israeli organization for technology transfer.
Prior to Yissum, Mr. Michlin practiced as a corporate lawyer, advising on major corporate matters including mergers and acquisitions, capital raising and initial public offerings for clients including Teva Pharmaceutical Industries.
Mr. Michlin is a lawyer and economist by training and holds an MBA from the Technion in high-tech company management.